Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02737631 · ClinicalTrials.gov registry record · NA

Human Repeat Insult Patch Test to Evaluate Personal Lubricants

A NA study of Edema and Erythema, sponsored by Church & Dwight Company.

Completed
Registry status
NA
Development phase
222
Enrollment target
1
Study location

NCT02737631 is a NA study of Edema and Erythema that has completed, run by Church & Dwight Company. The registered enrollment target is 222 participants, below the 448-participant average among 13 other Edema trials with a reported enrollment target (50% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02737631, a NA study of Edema and Erythema, has completed, sponsored by Church & Dwight Company.

COMPLETED
Registry status
NA
Development phase
222 participants
Enrollment target
1
Study location

Study Summary

The purpose of this test is to evaluate the sensitizing potential of a personal lubricant, as a result of repeated occlusive patch. The intervention will be applied for a total of 9 induction applications, followed by an approximately 2 week rest period, then followed by a 24-72 hour Challenge applications.

Conditions Studied

Interventions

  • DEVICE "Chameleon" Personal Lubricant

Study Locations (1)

New Jersey

  • Harrison Research Laboratories, Inc. - Union

Trial Details

FieldValue
Enrollment Target 222 participants
Start Date 2016-02
Est. Completion 2016-03
Phase NA

Sponsor

Church & Dwight Company

19 total trials

What the Registry Record Tells You About NCT02737631

The ClinicalTrials.gov registry entry for NCT02737631 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 448-participant average among 13 other Edema trials with a reported enrollment target (50% lower). The listed sponsor is Church & Dwight Company, which has 19 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Edema appearing as the primary indexed condition, and to 1 intervention - of which "Chameleon" Personal Lubricant is the first listed.

NCT02737631 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT02737631 about?

NCT02737631 is a clinical study titled "Human Repeat Insult Patch Test to Evaluate Personal Lubricants". The purpose of this test is to evaluate the sensitizing potential of a personal lubricant, as a result of repeated occlusive patch. The intervention will be applied for a total of 9 induction applications, followed by an approximately 2 week rest period, then followed by a 24-72 hour Challenge appli...

What is the current status of trial NCT02737631?

This trial is currently completed. It is a NA study. The enrollment target is 222 participants. The study started on 2016-02. Estimated completion is 2016-03.

What conditions does trial NCT02737631 study?

This clinical trial studies the following conditions: Edema, Erythema.

What interventions are being tested in trial NCT02737631?

The interventions under investigation include: "Chameleon" Personal Lubricant (DEVICE).

Who is sponsoring clinical trial NCT02737631?

This trial is sponsored by Church & Dwight Company, which has 19 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02737631 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Edema

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.